ES2986421T3 - Método de tratamiento de tumores P53 WT - Google Patents

Método de tratamiento de tumores P53 WT Download PDF

Info

Publication number
ES2986421T3
ES2986421T3 ES19805046T ES19805046T ES2986421T3 ES 2986421 T3 ES2986421 T3 ES 2986421T3 ES 19805046 T ES19805046 T ES 19805046T ES 19805046 T ES19805046 T ES 19805046T ES 2986421 T3 ES2986421 T3 ES 2986421T3
Authority
ES
Spain
Prior art keywords
tumor
treatment
inhibitor
ck1a
mdm4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19805046T
Other languages
English (en)
Spanish (es)
Inventor
Jingwei Cheng
James Decaprio
Donglim Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2986421T3 publication Critical patent/ES2986421T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES19805046T 2018-10-30 2019-10-28 Método de tratamiento de tumores P53 WT Active ES2986421T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752382P 2018-10-30 2018-10-30
PCT/US2019/058319 WO2020092221A1 (en) 2018-10-30 2019-10-28 Method of treatment of p53 wt tumors

Publications (1)

Publication Number Publication Date
ES2986421T3 true ES2986421T3 (es) 2024-11-11

Family

ID=68582462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19805046T Active ES2986421T3 (es) 2018-10-30 2019-10-28 Método de tratamiento de tumores P53 WT

Country Status (10)

Country Link
US (1) US12115151B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873460B1 (cg-RX-API-DMAC7.html)
JP (2) JP7653907B2 (cg-RX-API-DMAC7.html)
KR (1) KR102879859B1 (cg-RX-API-DMAC7.html)
CN (1) CN112996503A (cg-RX-API-DMAC7.html)
AU (1) AU2019369216B2 (cg-RX-API-DMAC7.html)
CA (1) CA3115716A1 (cg-RX-API-DMAC7.html)
ES (1) ES2986421T3 (cg-RX-API-DMAC7.html)
IL (1) IL282485B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020092221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6(Vps39)作为靶点在药物筛选、基因编辑以及疾病治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3541387T3 (pl) * 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53

Also Published As

Publication number Publication date
JP2025026846A (ja) 2025-02-26
JP2022505884A (ja) 2022-01-14
CA3115716A1 (en) 2020-05-07
IL282485B1 (en) 2025-05-01
KR20210087958A (ko) 2021-07-13
US20210379039A1 (en) 2021-12-09
AU2019369216A1 (en) 2021-05-20
IL282485A (en) 2021-06-30
KR102879859B1 (ko) 2025-11-04
JP7653907B2 (ja) 2025-03-31
EP3873460A1 (en) 2021-09-08
AU2019369216B2 (en) 2022-05-19
EP3873460B1 (en) 2024-06-12
WO2020092221A1 (en) 2020-05-07
IL282485B2 (en) 2025-09-01
US12115151B2 (en) 2024-10-15
CN112996503A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
US20130288980A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
US20210251988A1 (en) Methods of treating disorders
JP2025026846A (ja) p53WT腫瘍の処置の方法
SG189901A1 (en) Combination treatment of cancer
WO2013152038A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
US11246856B2 (en) Methods of treating resistant cancers
CA2883985A1 (en) Aminoheteroaryl compounds as mth1 inhibitors
Xu et al. Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity
Zhang et al. MGMT activated by Wnt pathway promotes cisplatin tolerance through inducing slow-cycling cells and nonhomologous end joining in colorectal cancer
Brunet et al. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Tokumoto et al. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth
HK40048199A (en) Method of treatment of p53 wt tumors
HK40048199B (en) Method of treatment of p53 wt tumors
Nandi Cellular and metabolic reprogramming in breast Cancer and its therapeutic implications
Benítez García Identification and Preclinical Evaluation of Asenapine Maleate as a Direct Survivin Inhibitor for Lung Cancer Therapy and Sensitization to Proapoptotic Treatments
Jones Targeting Vulnerabilities in Cell State and Calcium Signaling for the Treatment of Lung Cancer
Heisey Targeted Therapies for EWSR1-FLI1 Translocated Ewing Family of Tumors
WO2025056601A1 (en) Pharmaceutical combination product comprising kinase inhibitor and autophagy inducer and uses thereof
Manara Deciphering the Impact of Translation Inhibition in Blood Malignancies
He Unraveling PI5P4K’s Immunomodulatory Role in Lung Cancer Tumor Microenvironment⎯ A Druggable Target to Promote Anti-Tumor Immunity
Perl Leveraging Small Molecule Activators of Protein Phosphatase 2A (PP2A) to Elucidate PP2As Role in Regulating DNA Replication and Apoptosis
Prince et al. Women in molecular and cellular oncology, volume II: 2022
Shi et al. LINC02470 impairs natural killer cell cytotoxicity by epigenetically targeting the natural cytotoxicity triggering receptor 1
Lukošiūtė-Urbonienė Effects of Epigenetic Alterations on the Apoptosis Regulating Proteins in Pancreatic Cancer
ES2619571T3 (es) Método para la terapia del cáncer